A novel option for prandial insulin therapy: inhaled insulin

Postgraduate Medicine

Volumn 128, Issue 8, 2016, Pages 839-847

  Dailey, George ^a   Ahmad, Aakif ^a   Polsky, Sarit ^b   Shah, Viral ^b  

^a SCRIPPS CLINIC   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Hypoglycemia; inhaled insulin; oral antidiabetes drugs; prandial insulin; type 2 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN LISPRO; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

AREA UNDER THE CURVE; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FORCED EXPIRATORY VOLUME; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INHALER; INSULIN TREATMENT; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SORE THROAT; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, SHORT-ACTING; QUALITY OF LIFE;

EID: 84988695771     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2016.1229555     Document Type: Review

References (59)

1. IDF diabetes atlas. 6th ed. Brussels (Belgium):International Diabetes Federation; 2013.
2. R.R.Holman, S.K.Paul, M.A.Bethel, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
3. D.M.Nathan, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years:overview. Diabetes Care. 2014;37:9–16.
4. M.S.Rendell, L.Jovanovic Targeting postprandial hyperglycemia. Metabolism. 2006;55:1263–1281.
5. F.Cavalot, A.Pagliarino, M.Valle, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up:lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care. 2011;34:2237–2243.
6. N.G.Clark. Postprandial blood glucose, cardiovascular events, and all-cause mortality:how do we use postprandial glucose in clinical practice? Clin Diabetes. 2012;30:67–69.
7. M.Mata-Cases, D.Mauricio, J.Franch-Nadal. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets. J Diabetes. 2016 Jan 8. doi:10.1111/1753-0407.12373. [Epub ahead of print].
8. D.Gordin, M.Saraheimo, J.Tuomikangas, et al. Influence of postprandial hyperglycemic conditions on arterial stiffness in patients with type 2 diabetes. J Clin Endocrinol Metab. 2016;101:1134–1143.
9. F.Cavalot. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab. 2013;15(Suppl 2):3–8.
10. G.Sartore, N.C.Chilelli, S.Burlina, et al. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013;50:437–442.
11. A.J.Garber, M.J.Abrahamson, J.I.Barzilay, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 Executive Summary. Endocr Pract. 2016;22:84–113.
12. S.E.Inzucchi, R.M.Bergenstal, J.M.Buse, et al. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
13. R.J.Schrot. Targeting plasma glucose:preprandial versus postprandial. Clin Diabetes. 2004;22:169–172.
14. S.E.Inzucchi, R.M.Bergenstal, J.B.Buse, et al. Management of hyperglycemia in type 2 diabetes:a patient-centered approach:position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
15. S.Subramanian, I.B.Hirsch. Personalized diabetes management:moving from algorithmic to individualized therapy. Diabetes Spectr. 2014;27:87–91.
16. M.C.Riddle. The transition from oral agents to combination insulin/oral therapy. In:M.N.Feinglos, M.A.Bethel, editors. Contemporary endocrinology:Type 2 diabetes mellitus:an evidence-based approach to practical management. Totowa (NJ):Humana Press; 2008. p. 169–181.
17. W.H.Polonsky, L.Fisher, S.Guzman, et al. Psychological insulin resistance in patients with type 2 diabetes. The scope of the problem. Diabetes Care. 2005;28:2543–2545.
18. M.Peyrot, R.R.Rubin, T.Lauritzen, et al. Resistance to insulin therapy among patients and providers. Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2005;28:2673–2679.
19. A.J.Kugler, K.L.Fabbio, D.Q.Pham, et al. Inhaled technosphere insulin:a novel delivery system and formulation for the treatment of types 1 and 2 diabetes mellitus. Pharmacotherapy. 2015;35:298–314.
20. T.Heise, L.F.Meneghini. Insulin stacking versus therapeutic accumulation:understanding the differences. Endocr Pract. 2014;20:75–83.
21. US FDA. Press Announcements:FDA approves Afrezza to treat diabetes; [cited 2014 Jun 27; updated 2015 Dec 17]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122
22. S.Kokić, D.Buković, M.Radman, et al. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Coll Antropol. 2003;27:181–187.
23. J.Rosenstock, B.Zinman, L.J.Murphy, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes:a randomized, controlled trial. Ann Intern Med. 2005;143:549–558.
24. L.Pala, E.Mannucci, I.Dicembrini, et al. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;78:132–135.
25. R.R.Holman, K.I.Thorne, A.J.Farmer, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–1730.
26. K.Yamashiro, F.Ikeda, Y.Fujitani, et al. Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes. J Diabetes Investig. 2010;1:149–153.
27. S.A.Brunton. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. Postgrad Med. 2012;124:74–83.
28. O.P.Hamnvik, G.T.McMahon. Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med. 2009;76:234–243.
29. Y.F.Du, H.Y.Ou, E.A.Beverly, et al. Achieving glycemic control in elderly patients with type 2 diabetes:a critical comparison of current options. Clin Interv Aging. 2014;9:1963–1980.
30. P.Phillips Type 2 diabetes - failure, blame and guilt in the adoption of insulin therapy. Rev Diabet Stud. 2005;2:35–39.
31. M.Peyrot, R.R.Rubin, D.F.Kruger, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33:240–245.
32. M.Peyrot, A.H.Barnett, L.F.Meneghini, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682–689.
33. M.J.Davies, J.J.Gagliardino, L.J.Gray, et al. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus:a systematic review. Diabet Med. 2013;30:512–524.
34. L.A.Donnelly, A.D.Morris, J.M.Evans, et al. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345–350.
35. L.E.García-Pérez, M.Alvarez, T.Dilla, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175–194.
36. N.Sarala, G.Bengalorkar, K.Bhuvana. Technosphere:new drug delivery system for inhaled insulin. Fut Prescriber. 2012;13:14–16.
37. J.P.Cassidy, N.Amin, M.Marino, et al. Insulin lung deposition and clearance following Technosphere Insulin inhalation powder administration. Pharm Res. 2011;28:2157–2164.
38. G.Ledet, R.A.Graves, L.A.Bostanian, et al. A second-generation inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2015;72:1181–1187.
39. M.K.Marino, J.P.Cassidy, C.C.Smutney, et al. Bioequivalence and dose proportionality of AFREZZA® inhalation powder administered using a Gen2 inhaler compared to the Medtone® inhaler. Presented at the Diabetes Technology Meeting; 2010 Nov 11–13; Bethesda (MD). Poster #142. Available from:http://www.mannkindcorp.com/collateral/documents/english-us/2010-dts-poster-142-be-final-lr-11.10.10.pdf.
40. J.M.Tibaldi. Evolution of insulin:from human to analog. Am J Med. 2014;127(10 Suppl):S25–38.
41. K.Rave, E.Potocka, L.Heinemann, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11:715–720.
42. K.Rave, T.Heise, L.Heinemann, et al. Inhaled Technosphere insulin in comparison to subcutaneous regular insulin:time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2:205–212.
43. Humalog Prescribing Information. 2015 [cited 2015 Dec17]. Available from: http://pi.lilly.com/us/humalog-pen-pi.pdf
44. Apidra Prescribing Information. 2009 [cited 2015 Dec17]. Available from: http://medconnections.com/drugs/pdf/apidra.pdf
45. Novalog Prescribing Information. 2010 [cited 2015 Dec17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214655.pdf
46. Afrezza Prescribing Information. 2014 [cited 2015 Dec17]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdf
47. J.Rosenstock, R.Bergenstal, R.A.Defronzo, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31:2177–2182.
48. M.Rendell. Technosphere inhaled insulin (Afrezza). Drugs Today (Barc). 2014;50:813–827.
49. P.Raskin, S.Heller, M.Honka, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment:a randomized trial. Diabetes Obes Metab. 2012;14:163–173.
50. US FDA. Briefing Document:Endocrinologic and Metabolic Drugs Advisory Committee Meeting, April 1, 2014 [cited 2015 Dec 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390864.pdf
51. B.W.Bode, J.B.McGill, D.L.Lorber, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes:a randomized 24-week trial. Diabetes Care. 2015;38:2266–2273.
52. J.Rosenstock, D.L.Lorber, L.Gnudi, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes:a multicentre randomised trial. Lancet. 2010;375:2244–2253.
53. J.Rosenstock, D.Franco, V.Korpachev, et al. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015;38:2274–2281.
54. A.G.Pittas, G.P.Westcott, E.M.Balk. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes:a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:886–894.
55. D.B.Muchmore, D.E.Vaughn. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J Diabetes Sci Technol. 2012;6:764–772.
56. H.Zisser, L.Jovanovic, K.Markova, et al. Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2012;14:997–1001.
57. M.Peyrot, R.R.Rubin. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther. 2010;12:49–55.
58. C.J.Tack, V.Christov, B.E.de Galan, et al. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2:47–57.
59. Sanofi-Aventis US. Dosing Guide for Afrezza®. 2015 [cited 2016 Jan6]. Available from: http://hcp.afrezza.com/AfrezzaConfigurationChart.pdf